Syphilis Testing Market (2026 - 2033) Size, Share & Trends Analysis Report By Technology (Molecular Diagnostics, Immunoassay, Others), By Location Of Testing (Laboratory Testing, Point of Care Testing), By Region, And Segment Forecasts

Syphilis Testing Market Summary

The global syphilis testing market size was valued at USD 1.5 billion in 2025 and is projected to grow from USD 1.6 billion in 2026 to USD 2.3 billion by 2033, at a CAGR of 5.2% from 2026 to 2033. The North America syphilis testing market held the largest share of 36.32% of the global market in 2025. Key market drivers for dual HIV/syphilis rapid diagnostics include the rising global burden of congenital syphilis and HIV co-infections, which continue to cause significant adverse pregnancy outcomes.

Syphilis, once considered a disease of the past, has reemerged as a significant public health and market concern in North America and globally.

While the widespread use of penicillin in the mid-20th century had nearly eliminated syphilis in high-income countries, recent years have seen a sharp resurgence. In the U.S., reported cases increased by more than 80% between 2018 and 2022, rising from approximately 115,000 to over 207,000-the highest level since the 1950s. Of particular concern is congenital syphilis, which grew by 183% during the same period, reflecting gaps in maternal screening and early intervention.

In Canada, rising incidence in the Prairie provinces and northern territories-particularly among Indigenous populations further highlights disparities in access to timely diagnostics and treatment. These epidemiological shifts are creating heightened demand for innovative diagnostic solutions, decentralized testing models, and scalable public health interventions, positioning the infectious disease diagnostics market for accelerated growth.

Market Dynamics

Market Concentration & Characteristics

Innovation is reshaping dual rapid testing, with companies like MedMira launching the Multiplo Rapid TP/HIV Test, capable of detecting both HIV-1/2 and syphilis antibodies from a single finger-prick with 100% HIV accuracy and 98% syphilis accuracy. Already deployed in Europe and Colombia and recently approved by Health Canada (Dec 2024), such devices offer immediate results without refrigeration. This innovation supports decentralized care, bridges gaps in underserved communities, and advances EMTCT goals.

M&A and collaborations are driving accessibility and affordability. For instance, in November 2021, MedAccess, CHAI, and SD Biosensor formed a partnership to distribute the STANDARD Q HIV/Syphilis Combo Test at under US$1 across 100+ LMICs. While outright acquisitions are moderate, such global collaborations mirror consolidation effects, enabling scale, affordability, and distribution synergies. Larger diagnostics firms are expected to target similar partnerships or acquisitions to strengthen infectious disease testing portfolios.

Regulation remains a catalyst, shaping adoption and market entry. Health Canada’s approval (Dec 2024) of MedMira’s dual test followed a 1,500+ subject clinical study in Alberta (2020-2022) co-led by top institutions, ensuring credibility. Similarly, the WHO prequalification of SD Biosensor’s STANDARD Q combo test allowed procurement by donor-funded programs in LMICs. Such regulatory endorsements reduce market hesitancy, ensure compliance with global EMTCT strategies, and create strong differentiation for approved products.

Substitution risk exists but remains manageable. Traditional ELISA and PCR assays deliver gold-standard accuracy but are limited by infrastructure requirements and slower turnaround times. Rapid combo tests, like MedMira’s Multiplo and SD Biosensor’s STANDARD Q, provide point-of-care results in under 20 minutes at a fraction of the cost. However, emerging HIV self-tests and multiplex molecular platforms could act as substitutes. To maintain an edge, rapid test developers emphasize affordability (e.g., 32% price cut via CHAI-MedAccess) and ease of use.

End-users are highly concentrated in public health agencies, NGOs, and maternal health programs. For example, the CHAI-MedAccess-SD Biosensor partnership directly targets antenatal care in 100+ LMICs, aligning with WHO EMTCT goals. In high-income regions, adoption depends on government approvals, as seen with Health Canada’s 2024 clearance enabling rollout in Canadian hospitals and clinics. Indigenous populations in Canada’s Prairie provinces, experiencing disproportionately higher infection rates, highlight the need for targeted community health programs.

Technology Insights

The immunoassay segment led the market with the largest revenue share of 71.20% in 2025. Its dominance stems from widespread clinical adoption, established use in hospital laboratories, cost-effectiveness, and compatibility with high-throughput platforms. Immunoassays, including ELISA and chemiluminescent assays, are considered the gold standard for antibody detection, particularly in confirmatory testing. Their strong regulatory acceptance and extensive integration into public health programs further consolidate market leadership.

The molecular diagnostics segment is anticipated to grow at the fastest CAGR during the forecast period, driven by rising demand for early, highly sensitive detection of infections. PCR and next-generation sequencing (NGS)-based tools are gaining traction, particularly in monitoring viral load, resistance mutations, and detecting low-titer infections that may be missed by serology. Growth is accelerated by decentralization trends, falling costs of molecular platforms, and integration into point-of-care and multiplex assays. These attributes make molecular diagnostics critical in addressing gaps left by traditional methods, particularly in mother-to-child transmission screening and high-burden geographies.

Location of Testing Insights

The laboratory-based testing segment led the market with the largest revenue share of 79.56% in 2025, owing to its entrenched role as the clinical gold standard. Centralized laboratories and hospital-based diagnostic centers rely heavily on automated immunoassays, ELISAs, and confirmatory treponemal/non-treponemal workflows that ensure high accuracy and consistency. These platforms support high-volume testing, making them particularly valuable in national screening initiatives and prenatal care programs where reliability is paramount.

In the United States, laboratory giants such as Quest Diagnostics and LabCorp have built extensive syphilis testing infrastructure, often bundled with comprehensive STD panels that streamline testing workflows for clinicians. In Canada, providers such as LifeLabs and provincial public health labs dominate, integrating syphilis testing into routine sexual health and antenatal programs. Laboratories also benefit from established reimbursement pathways and integration with electronic medical records (EMRs), reinforcing their central role in healthcare systems.

Despite the growth of decentralized alternatives, laboratories continue to maintain their dominance because of their unmatched ability to handle confirmatory testing, complex case management, and integration with advanced molecular diagnostics. Particularly for high-risk populations and congenital syphilis investigations, laboratory workflows remain essential for providing definitive results.

The point-of-care (POC) testing segment is anticipated to grow at the fastest CAGR during the forecast period, reflecting shifting public health priorities toward accessibility, speed, and patient-centered care. The surge in congenital syphilis, which demands immediate detection and treatment, has highlighted the limitations of lab-centric models that rely on multiple visits and long turnaround times. In response, both regulators and companies are accelerating the adoption of rapid and at-home testing solutions.

A landmark example is Health Canada’s approval (December 2024) of MedMira’s Multiplo Rapid TP/HIV Test, a dual-purpose finger-prick device that delivers near-instant results for both HIV and syphilis, with no special storage requirements. Already in use across Europe and Colombia, the device is now positioned to close diagnostic gaps in both urban hospitals and remote Canadian communities. Similarly, in August 2024, the U.S. FDA authorized NOWDiagnostics’ First To Know Syphilis Test through the De Novo pathway, marking the first over-the-counter syphilis diagnostic available for at-home use. This regulatory milestone not only enables consumer-driven testing but also establishes a precedent for other developers to bring innovative syphilis POC solutions to market.

POC solutions are particularly critical in Indigenous and underserved communities across North America, where access to centralized laboratories is limited and travel times are prohibitive. Mobile outreach programs in regions like the Navajo Nation in the U.S. and Prairie provinces in Canada are leveraging these rapid devices to deliver same-day testing and treatment, reducing loss to follow-up.

Globally, WHO-endorsed dual HIV/syphilis combo tests, such as the STANDARD Q (SD Biosensor) supplied under the CHAI-MedAccess partnership, are further demonstrating the role of POC platforms in advancing elimination of mother-to-child transmission (EMTCT) targets. As syphilis rates rise, the market is shifting toward hybrid models, where centralized labs maintain their dominance for confirmatory and large-scale screening, while POC testing grows rapidly as a frontline solution to improve accessibility, equity, and speed of diagnosis.

Regional Insights

North America dominated the global syphilis testing market with the largest revenue share of 36.32% in 2025. The U.S. drives this leadership through high testing volumes at Quest Diagnostics, Labcorp, and public health laboratories, where syphilis is included in comprehensive STD panels. Recent FDA clearances of innovative diagnostics, such as NOWDiagnostics’ at-home syphilis test, are expanding access and creating a consumer-directed market. In Canada, LifeLabs and provincial health authorities emphasize antenatal screening and community outreach programs, particularly in the Prairie provinces. Growing congenital syphilis rates and strong federal funding continue to fuel demand across both laboratory and point-of-care channels.

U.S. Syphilis Testing Market Trends

The syphilis testing market in the U.S. accounted for the largest market revenue share in North America in 2025, driven by a sharp epidemiologic rebound-reported cases rose ~80% from 2018-2022-plus major policy and regulatory responses. The FDA’s August 2024 De Novo authorization for NOWDiagnostics’ at-home antibody test created an OTC consumer testing channel, while NIH investments ($2.4M in 2024; $2.7M in 2025 grants) are accelerating next-gen molecular and electrochemical POC diagnostics. Implementation models (e.g., University of Chicago ED opt-in screening; Navajo Nation mobile outreach) emphasize decentralized testing and same-day treatment to reduce loss to follow-up. Persistent challenges-Bicillin L-A shortages, declining CDC STD prevention funding, and congenital syphilis spikes-sustain demand for rapid, confirmatory, and field-deployable tests.

Europe Syphilis Testing Market Trends

The syphilis testing market in Europe is shaped by growing incidence and strong national health systems prioritizing targeted screening. The UK and Germany report steady case increases, prompting expansion of free sexual health services and antenatal programs. Laboratories dominate with automated immunoassays, while CE-marked rapid tests are used in community clinics. Digital integration into public health networks improves surveillance and contact tracing. Procurement remains cost-sensitive, requiring suppliers to deliver value-driven pitches. Future growth is likely through dual HIV/syphilis rapid tests in antenatal care, and enhanced use of digital reporting platforms. Strong regulation and robust reimbursement systems create barriers but ensure market stability.

The UK syphilis testing market shows modest upticks in syphilis diagnoses (early-stage cases: 9,535 in 2024 vs 9,375 in 2023; overall cases 13,030 vs 12,456). Public programs emphasize free, confidential testing and targeted messaging to high-risk groups (MSM, young adults). Policy momentum-NHS rollout of gonorrhea vaccination programs-illustrates prevention orientation, while surveillance highlights rising antibiotic resistance in gonorrhea. Market opportunities center on integrated sexual-health POC devices and digital linkage-to-care solutions. Buyers favor validated rapid dual tests for antenatal screening and community clinics; regulatory acceptance and NHS procurement cycles will determine commercial scale-up.

The syphilis testing market in Germany accounted for a significant share of the European market in 2025. The syphilis landscape mirrors broader EU increases in bacterial STIs; testing and genomic surveillance (WGS) are expanding to track resistant strains. Clinical laboratories remain primary purchasers, using automated immunoassays for screening and molecular techniques for complex cases. Growing public-health focus on MSM and young adult engagement, plus improved surveillance, is creating demand for rapid POC diagnostics in sexual-health clinics and outreach programs. Vendors that combine high sensitivity with integration into municipal public health reporting and partner notification workflows will find traction as Germany scales targeted screening and antimicrobial resistance monitoring.

Asia Pacific Syphilis Testing Market Trends

The syphilis testing market in the Asia Pacific is projected to grow at the fastest CAGR over the forecast period. Asia-Pacific presents diverse dynamics, with China and Japan leading in laboratory-based immunoassays and antenatal screening, while Southeast Asia emphasizes cost-effective rapid testing. Rising incidence, urbanization, and maternal health programs drive demand. China’s provincial procurement favors high-volume labs and WHO-prequalified dual tests, while Japan expands targeted syphilis clinics but requires rigorous validation for new technologies. In lower-income countries, donor-driven programs supply affordable rapid kits for maternal health. Market opportunities lie in combining rapid testing with digital follow-up to ensure timely treatment. Strategic partnerships and localized regulatory alignment are critical for success in this fragmented yet high-growth regional market

The China syphilis testing market is characterized by expanding laboratory capacity and rapid scale-up of point-of-care screening in urban and provincial health systems. National antenatal screening initiatives and rising STI surveillance drive demand for affordable dual HIV/syphilis rapid assays, lab immunoassays, and molecular confirmatory tests. Manufacturers that offer WHO-aligned, low-cost combo tests and scalable platforms can access procurement through provincial health networks. Challenges include bridging urban-rural access gaps and ensuring confirmatory lab follow-through; opportunities exist to integrate POC testing with telemedicine and maternal health programs.

The syphilis testing market in Japan is anticipated to grow at a significant CAGR during the forecast period.Japan has responded to localized outbreaks-Tokyo reported 3,667 syphilis cases in 2022 (a 50% rise from 2021)-by expanding testing access (extended clinic hours, holiday/Sunday services) and pairing syphilis with HIV screening. The market is conservative, favoring laboratory immunoassays for confirmatory diagnosis, but authorities are piloting POC expansions to improve early detection in young adults. Vendors should prioritize regulatory compliance, clinician education, and demonstration projects tied to prenatal care; culturally sensitive outreach and anonymity-preserving distribution channels will support uptake among younger and stigmatized populations.

Latin America Syphilis Testing Market Trends

The syphilis testing market in Latin America is anticipated to grow at a substantial CAGR during the forecast period. Latin America, led by Brazil, prioritizes syphilis testing within maternal and child health programs due to high congenital syphilis rates. Public procurement dominates, with Ministries of Health sourcing WHO-prequalified dual HIV/syphilis tests for antenatal care. Laboratories remain important for confirmatory testing, but POC diagnostics in community clinics are increasingly adopted to enable same-visit treatment initiation. Brazil’s federal health system purchases at scale, driving strong demand for affordable, reliable supply chains. The region’s price sensitivity favors cost-effective solutions, and partnerships with local distributors and NGOs are essential. Demonstrating improved maternal outcomes is key to sustained growth and procurement renewals.

The Brazil syphilis testing market is growing at a rapid pace. Brazil’s public health priorities emphasize antenatal screening and reducing congenital syphilis, creating sizable demand for dual HIV/syphilis rapid tests and low-cost POC kits. Regional initiatives and NGO partnerships (mirrored by CHAI/MedAccess/SD Biosensor models) have created price-sensitive procurement channels across LMICs. Large public purchasers (Ministry of Health, regional health secretariats) prioritize WHO-prequalified products that enable on-site testing in primary care and maternity clinics. Vendors that can combine cost competitiveness, supply reliability, and integration with prenatal programs will be well-positioned to scale across Brazil and neighboring markets.

Middle East and Africa Syphilis Testing Market Trends

The syphilis testing market in the Middle East and Africa is expected to grow significantly during the forecast period. In Africa, syphilis remains a major driver of adverse birth outcomes ~11% of stillbirths are attributable to syphilis, so maternal screening is a key market. WHO and donor-funded procurement drive uptake of low-cost, WHO-prequalified combo tests (e.g., STANDARD Q). Infrastructure constraints favor POC and rapid combo diagnostics that do not require cold chain or complex lab infrastructure. In the Middle East, markets are heterogeneous: wealthier GCC countries invest in lab and molecular capacity, while low-resource countries rely on NGO and donor programs. Scalability depends on procurement frameworks, donor support, and local capacity-building.

The Saudi Arabia syphilis testing market is anticipated to grow at a significant CAGR during the forecast period. Saudi Arabia’s health system emphasizes centralized lab capacity and antenatal screening in public hospitals; demand for high-quality immunoassays and confirmatory molecular testing remains strong. At the same time, Gulf Cooperation Council (GCC) initiatives and private hospitals are open to rapid POC solutions for screening travelers, migrant worker clinics, and perinatal care. Market entry requires regulatory clearance, adherence to national procurement, and partnerships with major hospital groups. Opportunities exist for accredited dual HIV/syphilis rapid tests that meet Saudi regulatory standards and can be deployed in maternal health and occupational-health screening programs.

Key Syphilis Testing Company Insights

Market leaders are engaged in extensive R&D to develop technologically advanced, cost-efficient testing products. Besides, several organizations are incorporating strategies such as mergers & acquisitions to expand their market presence and are anticipated to create significant growth opportunities over the forecast period. For instance, in May 2023, Charles Thermo Fisher Scientific, Inc. entered into a partnership with Pfizer Inc. to enhance the availability of localized access to next-generation sequencing-based testing for cancer patients in international markets.

Competitive Benchmarking

Recent Developments

• In August 2024, the U.S. FDA authorized the First To Know Syphilis Test by NOWDiagnostics, Inc., the first over-the-counter, at-home syphilis antibody test. Using a finger-stick blood sample, it delivers results in 15 minutes, similar to pregnancy or COVID-19 home tests. Although it cannot differentiate between past and active infections, its approval via the De Novo pathway reflects regulatory recognition of urgent public health needs. This milestone lowers barriers for consumer-focused diagnostics and sets a precedent for rapid, accessible syphilis testing. Enabling at-home testing, it expands early detection, reduces transmission, and empowers individuals to seek timely care.

• In March 2025, in Canada, the Canadian Institutes of Health Research (CIHR), in partnership with Indigenous leaders, established the Ayaangwaamiziwin Center, a $7 million Indigenous-led initiative to combat syphilis in Prairie and northern communities. The program delivers culturally safe testing, treatment, and community-based care, addressing disproportionately high infection rates among Indigenous populations. By embedding community leadership and culturally appropriate approaches, it reduces barriers to access, improves follow-up adherence, and enhances trust in healthcare interventions. The initiative integrates modern diagnostics with mobile outreach strategies and local engagement, serving as a model for equitable public health interventions targeting vulnerable populations in both rural and urban settings.

Syphilis Testing Market Report Scope

Global Syphilis Testing Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global syphilis testing market based on technology, location of testing, cancer type, function, and region:

• Technology Outlook (Number of Tests in Million; Revenue, USD Million, 2021 - 2033)

  • Molecular Diagnostics

  • Immunoassay

  • Others

• Location of Testing Outlook (Number of Tests in Million; Revenue, USD Million, 2021 - 2033)

  • Laboratory Testing

    • Commercial/Private labs

    • Public Health Labs

  • Point of Care Testing

• Regional Outlook (Number of Tests in Million; Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Delivered Customizations

This report has been delivered with the following In-depth customizations